TABLE 1.
Summary of adverse respiratory outcomes in HNSCC patients
| Author | Study period | Registry/site | No. of HNSCC patients | Known treatment | Outcome a | Key findings |
|---|---|---|---|---|---|---|
| Hussain et al 32 | 1985 | Single institution | 662 hospital admissions | Not specified | Infections (all etiologies) | PNA made up 40% of infections |
| Argiris et al 26 | 1989‐1999 | Multi‐institutional | 324 | CRT | Noncancer mortality (respiratory etiology) | 21% (COPD, PNA, other respiratory causes made up 37% of deaths) |
| Baxi et al 3 | 1992‐2000 | SEER | 35 958 | Surgery 28% | Noncancer mortality | 23% (excluding CVD) (COPD, PNA, influenza made up 35% of deaths) |
| 2000‐2005 | RT 37% | Second cancer mortality | 23% (lung cancer made up 43% of deaths) | |||
| Surgery + RT 35% | ||||||
| Buitelaar et al 33 | 1993‐1998 | Single institution | 469 | Surgery | Respiratory complications | 11% (PNA made up 42% of complications) |
| Rose et al 7 | 1994‐2003 | SEER | 34 568 | Not specified | Noncancer mortality | 13.0% (95% CI, 12.6%‐13.3%) at 5 years (COPD made up 8.5% of deaths) |
| Second cancer mortality | 14.6% (95% CI,14.2%‐15.0%) at 5 years (lung cancer made up 46% of deaths) | |||||
| Kawakita et al 6 | 1996‐2012 | Utah population database | 1901 | Surgery 34% | Respiratory complications | HR 6.61 (95% CI, 5.99‐7.29) at 2 years (all respiratory diseases b ) |
| Surgery + RT 21% | HR 1.88 (95% CI, 1.66‐2.13) at 5+ years | |||||
| CRT 16% | ||||||
| Triple modality 11% | ||||||
| Shen et al 8 | 2000‐2010 | SEER | 23 494 | Surgery | Noncancer mortality | 12.7% (95% CI, 12.2%‐13.3%) at 5 years (lung cancer and COPD made up 18.9% of deaths) |
| Semenov et al 24 | 2003‐2008 | Nationwide inpatient sample | 93 663 | Surgery | PNA | 5% infectious |
| 1% aspiration | ||||||
| <1% ventilator associated | ||||||
| Mirabile et al 34 | 2005‐2009 | Single institution | 2288 hospital admissions | (C)RT | Infections (nosocomial, all etiologies) | Respiratory etiology made up 40% of infections |
| 2010‐2012 | ||||||
| Shirasu et al 35 | 2006‐2016 | Single institution | 374 | CRT | PNA (during therapy) | 25% HR 1.58 (P = .024) |
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, chemoradiation therapy; CVD, cardiovascular disease; HNSCC, head and neck squamous cell carcinoma; HR, hazard ratio; PNA, pneumonia; RT, radiation therapy; SEER, surveillance, epidemiology, and end results database.
a
Not necessarily reflective of the study's primary outcome.
b
HR individually elevated for respiratory infections, COPD, and aspiration pneumonitis at both time points.